Regeneron Buys the Pieces of 23andMe As it Goes From $6 Billion to Bankruptcy
23andMe has reached the end of the road and is scheduled to be acquired by Regeneron Pharmaceuticals following a protracted period of poor..
•
Last updated: Wednesday, June 4, 2025
Quick overview
- 23andMe has been acquired by Regeneron Pharmaceuticals for $256 million after filing for Chapter 11 bankruptcy, marking a significant decline from its previous $6 billion valuation.
- The company's downfall was exacerbated by a major data breach in 2023 that compromised the personal information of approximately 7 million customers, damaging consumer trust.
- Criticism over the limitations of its genetic reporting contributed to consumer dissatisfaction, as users expected more detailed ancestry information than what was provided.
- Regeneron plans to utilize 23andMe's extensive database of 15 million DNA samples for drug discovery and medical research, shifting the focus from consumer ancestry to therapeutic development.
23andMe has reached the end of the road and is scheduled to be acquired by Regeneron Pharmaceuticals following a protracted period of poor performance and strategic blunders.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
- Read our latest reviews on: Avatrade, Exness, HFM and XM
ABOUT THE AUTHOR
See More
Skerdian Meta
Lead Analyst
Skerdian Meta Lead Analyst.
Skerdian is a professional Forex trader and a market analyst. He has been actively engaged in market analysis for the past 11 years. Before becoming our head analyst, Skerdian served as a trader and market analyst in Saxo Bank's local branch, Aksioner. Skerdian specialized in experimenting with developing models and hands-on trading. Skerdian has a masters degree in finance and investment.
Related Articles
Sidebar rates
